The market has had a nice run over the past week and a half. However, I still remain cautious; there are still many shoes to drop Nike Free Run in Europe, and domestic economic growth seems like it will be tepid at best through the rest of 2011. For the time being, I am sticking with stocks with low valuations, steadily growing earnings and solid and increasing dividend yields. ABT has grown earnings an average of over 13% annually over the past five years, despite the recession, and it is selling at just over 10 times 2012 expected EPS. Abbott provides a low beta (.30), a dividend yield of 3.8%, and an AA Nike Free Run rated balance sheet. ABT has beat earnings estimates each of the last four quarters, and consensus EPS for 2011 and 2012 have risen over the Nike Free Run prior three months. Abbott Labs has raised its dividend payout an average of 10.5% annually over the past half decade. It sells for less than 10 times operating cash flow and is increasing earnings and revenues at a healthy rate, which should bode well for future dividend growth. ABT has a solid new product pipeline both in the pharmaceutical and medical device areas. S has a price target of $58 on ABT, and the mean consensus analyst target on the stock is just under $58 a share as well.